Optimized femto-LASIK maintains preexisting spherical aberration independent of refractive error.

John D. Au, Ronald R. Krueger

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To report the visual outcomes and change in spherical aberration in the first cohort of eyes treated at the Cole Eye Institute using the FS200 laser (Alcon Laboratories Inc). A chart review was performed on 100 eyes targeted for emmetropia with wavefront-optimized femto-LASIK using the WaveLight Allegretto Wave Eye-Q (Alcon Laboratories Inc) and FS200 lasers. Patients were subdivided into low (< -3.00 D, n = 23), moderate (-3.00 to -6.00 D, n = 45), and high myopia (> -6.00 D, n = 2). Pre- and 3- to 9-month postoperative wavefront aberrometry and uncorrected distance visual acuity (UDVA) were compared. An increase was found in spherical aberration of 0.03 +/- 0.02 microm (P = .14) for low myopia, but decreases were found of 0.01 +/- 0.01 microm (P = .45) for moderate myopia and 0.02 +/- 0.04 microm (P = .48) for high myopia. An increase in coma was noted of 0.02 +/- 0.02 microm (P = .37), 0.04 +/- 0.02 microm (P = .02), and 0.11 +/- 0.04 microm (P = .01) for low, moderate, and high myopes, respectively. An increase was found in total higher order aberrations of 0.05 +/- 0.04 microm (P = .17), 0.04 +/- 0.01 microm (P = .01), and 0.11-0.03 microm (P = .01) for low, moderate, and high myopes, respectively. Uncorrected distance visual acuity of 20/15 and 20/20 was achieved in 70% and 91% of low myopes, 58% and 93% of moderate myopes, and 34% and 78% of high myopes, respectively. Wavefront-optimized femto-LASIK with the WaveLight Allegretto Wave Eye-Q and FS200 lasers achieved excellent postoperative UDVA outcomes, with no significant induction of spherical aberration at all refractive errors.

Original languageEnglish (US)
Pages (from-to)S821-825
JournalUnknown Journal
Volume28
Issue number11 Suppl
DOIs
StatePublished - Nov 2012

Fingerprint

Laser In Situ Keratomileusis
Refractive Errors
Aberrations
Wavefronts
Visual Acuity
Lasers
Myopia
Aberrometry
Emmetropia
Coma

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

Optimized femto-LASIK maintains preexisting spherical aberration independent of refractive error. / Au, John D.; Krueger, Ronald R.

In: Unknown Journal, Vol. 28, No. 11 Suppl, 11.2012, p. S821-825.

Research output: Contribution to journalArticle

@article{fafb7c26bc804512b8191abe0c449185,
title = "Optimized femto-LASIK maintains preexisting spherical aberration independent of refractive error.",
abstract = "To report the visual outcomes and change in spherical aberration in the first cohort of eyes treated at the Cole Eye Institute using the FS200 laser (Alcon Laboratories Inc). A chart review was performed on 100 eyes targeted for emmetropia with wavefront-optimized femto-LASIK using the WaveLight Allegretto Wave Eye-Q (Alcon Laboratories Inc) and FS200 lasers. Patients were subdivided into low (< -3.00 D, n = 23), moderate (-3.00 to -6.00 D, n = 45), and high myopia (> -6.00 D, n = 2). Pre- and 3- to 9-month postoperative wavefront aberrometry and uncorrected distance visual acuity (UDVA) were compared. An increase was found in spherical aberration of 0.03 +/- 0.02 microm (P = .14) for low myopia, but decreases were found of 0.01 +/- 0.01 microm (P = .45) for moderate myopia and 0.02 +/- 0.04 microm (P = .48) for high myopia. An increase in coma was noted of 0.02 +/- 0.02 microm (P = .37), 0.04 +/- 0.02 microm (P = .02), and 0.11 +/- 0.04 microm (P = .01) for low, moderate, and high myopes, respectively. An increase was found in total higher order aberrations of 0.05 +/- 0.04 microm (P = .17), 0.04 +/- 0.01 microm (P = .01), and 0.11-0.03 microm (P = .01) for low, moderate, and high myopes, respectively. Uncorrected distance visual acuity of 20/15 and 20/20 was achieved in 70{\%} and 91{\%} of low myopes, 58{\%} and 93{\%} of moderate myopes, and 34{\%} and 78{\%} of high myopes, respectively. Wavefront-optimized femto-LASIK with the WaveLight Allegretto Wave Eye-Q and FS200 lasers achieved excellent postoperative UDVA outcomes, with no significant induction of spherical aberration at all refractive errors.",
author = "Au, {John D.} and Krueger, {Ronald R.}",
year = "2012",
month = "11",
doi = "10.3928/1081597X-20121005-02",
language = "English (US)",
volume = "28",
pages = "S821--825",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "11 Suppl",

}

TY - JOUR

T1 - Optimized femto-LASIK maintains preexisting spherical aberration independent of refractive error.

AU - Au, John D.

AU - Krueger, Ronald R.

PY - 2012/11

Y1 - 2012/11

N2 - To report the visual outcomes and change in spherical aberration in the first cohort of eyes treated at the Cole Eye Institute using the FS200 laser (Alcon Laboratories Inc). A chart review was performed on 100 eyes targeted for emmetropia with wavefront-optimized femto-LASIK using the WaveLight Allegretto Wave Eye-Q (Alcon Laboratories Inc) and FS200 lasers. Patients were subdivided into low (< -3.00 D, n = 23), moderate (-3.00 to -6.00 D, n = 45), and high myopia (> -6.00 D, n = 2). Pre- and 3- to 9-month postoperative wavefront aberrometry and uncorrected distance visual acuity (UDVA) were compared. An increase was found in spherical aberration of 0.03 +/- 0.02 microm (P = .14) for low myopia, but decreases were found of 0.01 +/- 0.01 microm (P = .45) for moderate myopia and 0.02 +/- 0.04 microm (P = .48) for high myopia. An increase in coma was noted of 0.02 +/- 0.02 microm (P = .37), 0.04 +/- 0.02 microm (P = .02), and 0.11 +/- 0.04 microm (P = .01) for low, moderate, and high myopes, respectively. An increase was found in total higher order aberrations of 0.05 +/- 0.04 microm (P = .17), 0.04 +/- 0.01 microm (P = .01), and 0.11-0.03 microm (P = .01) for low, moderate, and high myopes, respectively. Uncorrected distance visual acuity of 20/15 and 20/20 was achieved in 70% and 91% of low myopes, 58% and 93% of moderate myopes, and 34% and 78% of high myopes, respectively. Wavefront-optimized femto-LASIK with the WaveLight Allegretto Wave Eye-Q and FS200 lasers achieved excellent postoperative UDVA outcomes, with no significant induction of spherical aberration at all refractive errors.

AB - To report the visual outcomes and change in spherical aberration in the first cohort of eyes treated at the Cole Eye Institute using the FS200 laser (Alcon Laboratories Inc). A chart review was performed on 100 eyes targeted for emmetropia with wavefront-optimized femto-LASIK using the WaveLight Allegretto Wave Eye-Q (Alcon Laboratories Inc) and FS200 lasers. Patients were subdivided into low (< -3.00 D, n = 23), moderate (-3.00 to -6.00 D, n = 45), and high myopia (> -6.00 D, n = 2). Pre- and 3- to 9-month postoperative wavefront aberrometry and uncorrected distance visual acuity (UDVA) were compared. An increase was found in spherical aberration of 0.03 +/- 0.02 microm (P = .14) for low myopia, but decreases were found of 0.01 +/- 0.01 microm (P = .45) for moderate myopia and 0.02 +/- 0.04 microm (P = .48) for high myopia. An increase in coma was noted of 0.02 +/- 0.02 microm (P = .37), 0.04 +/- 0.02 microm (P = .02), and 0.11 +/- 0.04 microm (P = .01) for low, moderate, and high myopes, respectively. An increase was found in total higher order aberrations of 0.05 +/- 0.04 microm (P = .17), 0.04 +/- 0.01 microm (P = .01), and 0.11-0.03 microm (P = .01) for low, moderate, and high myopes, respectively. Uncorrected distance visual acuity of 20/15 and 20/20 was achieved in 70% and 91% of low myopes, 58% and 93% of moderate myopes, and 34% and 78% of high myopes, respectively. Wavefront-optimized femto-LASIK with the WaveLight Allegretto Wave Eye-Q and FS200 lasers achieved excellent postoperative UDVA outcomes, with no significant induction of spherical aberration at all refractive errors.

UR - http://www.scopus.com/inward/record.url?scp=84875682772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875682772&partnerID=8YFLogxK

U2 - 10.3928/1081597X-20121005-02

DO - 10.3928/1081597X-20121005-02

M3 - Article

C2 - 23447895

AN - SCOPUS:84875682772

VL - 28

SP - S821-825

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 11 Suppl

ER -